PayerTalkCE® Presents: Managed Care Strategies to Improve Outcomes for Macular Telangiectasia

Learn About:

Benefit design strategies that ensure access to appropriate and effective therapies
Multidisciplinary care approaches for patients with macular telangiectasia
Timely treatment of macular telangiectasia
Current and emerging macular telangiectasia treatment options

Expert Faculty Presenters


	Jay Chhablani, MD Professor of Ophthalmology University of Pittsburgh Director, Clinical Research Director, Choroidal Analysis and Research (CAR) Lab UPMC Eye Center Click here for biography

	Jeffrey D. Dunn, PharmD, MBA President and CEO Cooperative Benefits Group (CBG) Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
With agents in late-stage development for the treatment of MacTel, managed care professionals must remain informed regarding available clinical trial data and prepare to incorporate emerging treatments into coverage policies to optimize healthcare resources and improve patient outcomes. Managed care pharmacists and other payer professionals will receive knowledge on the timely diagnosis and appropriate treatment of MacTel, including the current and evolving clinical data, the need for multidisciplinary patient care, and benefit design strategies to ensure access to appropriate and effective MacTel therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

Describe the natural history, disease mechanisms, and clinical goals of timely treatment of macular telangiectasia
Review the safety and efficacy data for current and emerging macular telangiectasia treatment options
Describe the value of multidisciplinary care approaches for patients with macular telangiectasia to improve patient outcomes and coordination of care
Identify benefit design strategies that ensure access to appropriate and effective macular telangiectasia therapies

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-25-068-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Jeffrey D. Dunn, PharmD, MBA, faculty for this activity, has no relevant financial relationships.

Jay Chhablani, MD, faculty for this activity, has the following relevant financial relationships:

Consultant/Advisor/Speaker: AbbVie, B&L, Eyepoint, Erasca, Iveric Bio, OD-OS
Individual publicly traded stocks and stock options: Ocular Therapeutics

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

Please note: Registration for AMCP 2025 is NOT required to attend this symposium.